As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics:

• What are the unmet needs in 1L therapy?
• The KRAS G12C mutation landscape

For the first topic, we dive into the PD-1 example in metastatic melanoma and compare updated data from the newly approved combination, PD-1 + LAG-3, with the PD-1 + CTLA-4 combination. Furthermore, we highlight some novel PD-1 combination data we will see at ASCO. We also discuss the INAVO120 study in HR+/HER2- breast cancer and the MARIPOSA subgroup analysis in 1L EGFR mutated NSCLC.

Finally, we highlight a few abstracts that may pave the way for KRAS G12C inhibitors to move into earlier lines of therapy in NSCLC and some combination data with novel mechanisms.

« Back to podcast episodes list.